儿童暴发性心肌炎是儿童急性心肌炎中最严重的类型,以起病急骤、进展迅猛为特点,且临床表现不典型,常以心外表现为主,是一种极易误诊、漏诊的急症。若能早期识别暴发性心肌炎患儿并给予积极有效的治疗和生命支持,可显著降低其死亡率,远期的预后也相对良好。目前对于儿童FM的治疗方法主要采用机械循环支持、正性肌力药物、抗心律失常药物、抗病毒药物、免疫调节药物等治疗。目前免疫调节药物主要包括糖皮质激素、静脉丙种球蛋白、其他免疫抑制剂等。现国内外有报道表明,若在早期使用免疫调节治疗,可以显著改善FM患儿的心脏功能,降低住院期间死亡率。但鉴于国内外对于免疫调节治疗仍存有争议,尚未得到广泛认可,没有规范化治疗标准,该文就儿童FM应用免疫调节药物治疗进展进行综述。
Fulminant myocarditis (FM) is the most serious type of acute myocarditis in children, which is characterized by rapid onset, rapid progression, and lack of specificity in clinical manifestations, of-ten appears with extracardiac symptoms. It’s easy to be misdiagnosed and missed diagnosis. If the children with FM can be identified early and given actively effective treatment and life support, their mortality rate can be significantly reduced, and the long-term prognosis is relatively good. At present, the treatment of FM in children mainly use mechanical circulation support, inotropic drugs, antiarrhythmic drugs, antiviral drugs, immunomodulatory drugs and other treatments. Immunomodulatory drugs mainly include corticosteroids, intravenous immunoglobulin, and other immunosuppressants. Some reports at home and abroad show that if the immunomodulatory therapy is used in the early stage, it can significantly improve the cardiac function of the children with FM and reduce the mortality rate during the hospital period. In view of the controversy about immunomodulatory therapy at home and abroad, it has not been widely recognized, and without standardized treatment standard. This article reviews the progress of using immunomodulatory drugs in children with FM.
Advances in Immunomodulatory Treatment for Fulminant Myocarditis in Children
Jing Chen1, Xiaoyun Wu2*
1Department of Cardiology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing
2Department of Pediatric Medicine, Southern University of Science and Technology Hospital, Shenzhen Guangdong
Fulminant myocarditis (FM) is the most serious type of acute myocarditis in children, which is characterized by rapid onset, rapid progression, and lack of specificity in clinical manifestations, often appears with extracardiac symptoms. It’s easy to be misdiagnosed and missed diagnosis. If the children with FM can be identified early and given actively effective treatment and life support, their mortality rate can be significantly reduced, and the long-term prognosis is relatively good. At present, the treatment of FM in children mainly use mechanical circulation support, inotropic drugs, antiarrhythmic drugs, antiviral drugs, immunomodulatory drugs and other treatments. Immunomodulatory drugs mainly include corticosteroids, intravenous immunoglobulin, and other immunosuppressants. Some reports at home and abroad show that if the immunomodulatory therapy is used in the early stage, it can significantly improve the cardiac function of the children with FM and reduce the mortality rate during the hospital period. In view of the controversy about immunomodulatory therapy at home and abroad, it has not been widely recognized, and without standardized treatment standard. This article reviews the progress of using immunomodulatory drugs in children with FM.
陈 静,吴晓云. 儿童暴发性心肌炎免疫调节治疗进展Advances in Immunomodulatory Treatment for Fulminant Myocarditis in Children[J]. 临床医学进展, 2023, 13(01): 256-263. https://doi.org/10.12677/ACM.2023.131040
参考文献ReferencesGinsberg, F. and Parrillo, J.E. (2013) Fulminant Myocarditis. Critical Care Clinics, 29, 465-483.
<br>https://doi.org/10.1016/j.ccc.2013.03.004杜军保, 张清友. 暴发性心肌炎的诊断与紧急救治[J]. 实用儿科临床杂志, 2004, 19(11): 925-927.Hiroyuki, M., et al. (2016) Clinical Features of Acute and Fulminant Myo-carditis in Children—2nd Nationwide Survey by Japanese Society of Pediatric Cardiology and Cardiac Surgery. Circula-tion Journal, 80, 2362-2368.
<br>https://doi.org/10.1253/circj.CJ-16-0234易聪, 佘香, 易岂建. 222例儿童病毒性心肌炎临床分析[J]. 重庆医科大学学报, 2020,45(4): 459-463.夏源园, 龚方戚. 50例儿童暴发性心肌炎的临床特点及危险因素分析[C]//2018年浙江省医学会儿科学分会学术年会. 2018: 330-331.汤磊, 朱叶芳. 36例儿童暴发性心肌炎的临床分析[J]. 重庆医学, 2014, 43(31): 4241-4242.Sankar, J., Khalil, S., Jeeva, S.M., et al. (2011) Short-Term Outcomes of Acute Fulminant Myocarditis in Children. Pediatric Cardiology, 32, 885-890. <br>https://doi.org/10.1007/s00246-011-0007-8McCarthy, R.R., Boehmer, J.P., Hruban, R.H., et al. (2000) Long-Term Outcome of Fulminant Myocarditis as Compared with Acute (Nonfulminant) Myocarditis. The New England Journal of Medicine, 342, 690-695.
<br>https://doi.org/10.1056/NEJM200003093421003Amabile, N., Fraisse, A., Bouvenot, J., et al. (2006) Out-come of Acute Fulminant Myocarditis in Children. Heart, 92, 1269-1273. <br>https://doi.org/10.1136/hrt.2005.078402成人暴发性心肌炎诊断与治疗中国专家共识[J]. 中华心血管病杂志, 2017, 45(9): 742-752.Feldman, A.M. and McNamara, D. (2000) Myocarditis. The New England Journal of Medicine, 343, 1388-1398.
<br>https://doi.org/10.1056/NEJM200011093431908Cooper, L.J. (2009) Myocarditis. The New England Journal of Medicine, 360, 1526-1538.
<br>https://doi.org/10.1056/NEJMra0800028Maisch, B., Ruppert, V. and Pankuweit, S. (2014) Management of Fulminant Myocarditis: A Diagnosis in Search of Its Etiology but with Therapeutic Options. Current Heart Failure Re-ports, 11, 166-177.
<br>https://doi.org/10.1007/s11897-014-0196-6Barton, M., Finkelstein, Y., Opavsky, M.A., et al. (2008) Eosin-ophilic Myocarditis Temporally Associated with Conjugate Meningococcal C and Hepatitis B Vaccines in Children. The Pediatric Infectious Disease Journal, 27, 831-835.
<br>https://doi.org/10.1097/INF.0b013e31816ff7b2Enko, K., Tada, T., Ohgo, K.O., et al. (2009) Fulminant Eo-sinophilic Myocarditis Associated with Visceral Larva Migrans Caused by Toxocara canis Infection. Circulation Journal, 73, 1344-1348.
<br>https://doi.org/10.1253/circj.CJ-08-0334Izumi, T., Kodama, M. and Shibata, A. (1991) Experimental Giant Cell Myocarditis Induced by Cardiac Myosin Immunization. European Heart Journal, 12, 166-168. <br>https://doi.org/10.1093/eurheartj/12.suppl_D.166Swirski, F.K. and Nahrendorf, M. (2018) Cardioimmunolo-gy: The Immune System in Cardiac Homeostasis and Disease. Nature Reviews Immunology, 18, 733-744. <br>https://doi.org/10.1038/s41577-018-0065-8Hulsmans, M., Clauss, S., Xiao, L., et al. (2017) Macrophages Facilitate Electrical Conduction in the Heart. Cell, 169, 510-522. <br>https://doi.org/10.1016/j.cell.2017.03.050Pollack, A., Kontorovich, A.R., Fuster, V., et al. (2015) Viral My-ocarditis—Diagnosis, Treatment Options, and Current Controversies. Nature Reviews Cardiology, 12, 670-680. <br>https://doi.org/10.1038/nrcardio.2015.108Huber, S.A. and Lodge, P.A. (1984) Coxsackievirus B-3 Myocar-ditis in Balb/c Mice. Evidence for Autoimmunity to Myocyte Antigens. The American Journal of Pathology, 116, 21-29.Rose, N.R., Wolfgram, L.J., Herskowitz, A., et al. (1986) Postinfectious Autoimmunity: Two Distinct Phases of Coxsackievirus B3-Induced Myocarditis. Annals of the New York Academy of Sciences, 475, 146-156.
<br>https://doi.org/10.1111/j.1749-6632.1986.tb20864.xKuhl, U., Pauschinger, M., Schwimmbeck, P.L., et al. (2003) Interferon-Beta Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients with Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction. Circulation, 107, 2793-2798. <br>https://doi.org/10.1161/01.CIR.0000072766.67150.51卢少玲, 张烁. 病毒性心肌炎演变为扩张型心肌病的机制[J]. 心血管康复医学杂志, 2016, 25(3): 341-343.Liu, P.P. and Mason, J.W. (2001) Advances in the Un-derstanding of Myocarditis. Circulation, 104, 1076-1082.
<br>https://doi.org/10.1161/hc3401.095198Opavsky, M.A., Penninger, J., Aitken, K., et al. (1999) Susceptibility to Myocarditis Is Dependent on the Response of Alphabeta T Lymphocytes to Coxsackieviral Infection. Circulation Re-search, 85, 551-558.
<br>https://doi.org/10.1161/01.RES.85.6.551Jensen, L.D. and Marchant, D.J. (2016) Emerging Pharmacologic Targets and Treatments for Myocarditis. Pharmacology & Therapeutics, 161, 40-51. <br>https://doi.org/10.1016/j.pharmthera.2016.03.006Bozkurt, B., Colvin, M., Cook, J., et al. (2016) Current Di-agnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement from the American Heart Association. Circulation, 134, e579-e646.
<br>https://doi.org/10.1161/CIR.0000000000000455Li, S., Xu, S., Li, C., et al. (2019) A Life Support-Based Comprehensive Treatment Regimen Dramatically Lowers the In-Hospital Mortality of Patients with Fulminant Myocardi-tis: A Multiple Center Study. Science China Life Sciences, 62, 369-380. <br>https://doi.org/10.1007/s11427-018-9501-9Blagova, O., Nedostup, A., Kogan, E., et al. (2020) Immunosup-pressive Therapy of Biopsy Proved Immune-Mediated Lymphocytic Myocarditis in the Virus-Negative and Vi-rus-Positive Patients. Cardiovascular Pathology, 49, Article ID: 107260. <br>https://doi.org/10.1016/j.carpath.2020.107260Allen, S.F., Godley, R.W., Evron, J.M., et al. (2014) Acute Necrotizing Eosinophilic Myocarditis in a Patient Taking Garcinia cambogia Extract Successfully Treated with High-Dose Corticosteroids. The Canadian Journal of Cardiology, 30, 1713-1732. <br>https://doi.org/10.1016/j.cjca.2014.08.025Callan, P.D., Baltabaeva, A., Kamal, M., et al. (2017) Acute Fulmi-nant Necrotizing Eosinophilic Myocarditis: Early Diagnosis and Treatment. ESC Heart Failure, 4, 660-664. <br>https://doi.org/10.1002/ehf2.12146Yonenaga, A., Hasumi, E., Fujiu, K., et al. (2018) Prognostic Improve-ment of Acute Necrotizing Eosinophilic Myocarditis (ANEM) through a Rapid Pathological Diagnosis and Appropriate Therapy. International Heart Journal, 59, 641-646. <br>https://doi.org/10.1536/ihj.17-308Ekstrom, K., Lehtonen, J., Kandolin, R., et al. (2016) Long-Term Outcome and Its Predictors in Giant Cell Myocarditis. European Journal of Heart Failure, 18, 1452-1458. <br>https://doi.org/10.1002/ejhf.606Bjelakovic, B., Vukomanovic, V. and Jovic, M. (2016) Fulminant Myocarditis in Children Successfully Treated with High Dose of Methyl-Prednisolone. Indian Journal of Pediatrics, 83, 268-269.
<br>https://doi.org/10.1007/s12098-015-1831-2李骄. 儿童暴发性心肌炎67例临床分析[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2016.Esmel-Vilomara, R., Dolader, P., Izquierdo-Blasco, J., et al. (2022) Parvovirus B19 Myocarditis in Children: A Diagnostic and Therapeutic Approach. European Journal of Pediatrics, 181, 2045-2053.
<br>https://doi.org/10.1007/s00431-022-04406-xMaisch, B. and Pankuweit, S. (2012) Current Treatment Options in (Peri)myocarditis and Inflammatory Cardiomyopathy. Herz, 37, 644-656. <br>https://doi.org/10.1007/s00059-012-3679-9Anthony, R.M., Nimmerjahn, F., Ashline, D.J., et al. (2008) Re-capitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc. Science, 320, 373-376. <br>https://doi.org/10.1126/science.1154315Shioji, K., Kishimoto, C. and Sasayama, S. (2001) Fc Recep-tor-Mediated Inhibitory Effect of Immunoglobulin Therapy on Autoimmune Giant Cell Myocarditis: Concomitant Sup-pression of the Expression of Dendritic Cells. Circulation Research, 89, 540-546. <br>https://doi.org/10.1161/hh1801.096263Drucker, N.A., Colan, S.D., Lewis, A.B., et al. (1994) Gam-ma-Globulin Treatment of Acute Myocarditis in the Pediatric Population. Circulation, 89, 252-257. <br>https://doi.org/10.1161/01.CIR.89.1.252杨晓霞, 李忠义. 大剂量丙种球蛋白及甲基泼尼松龙冲击治疗小儿暴发性心肌炎32例临床分析[J]. 临床医药实践, 2011, 20(3): 197-198.Piccininni, J.A., Richmond, M.E., Cheung, E.W., et al. (2018) Influenza Myocarditis Treated with Antithymocyte Globulin. Pediatrics, 142, e20180884. <br>https://doi.org/10.1542/peds.2018-0884Barry, T., Gallen, R., Freeman, C., et al. (2021) Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review. The American Journal of the Medical Sciences, 362, 424-432. <br>https://doi.org/10.1016/j.amjms.2021.04.018Huang, X., Sun, Y., Su, G., et al. (2019) Intravenous Immuno-globulin Therapy for Acute Myocarditis in Children and Adults. International Heart Journal, 60, 359-365. <br>https://doi.org/10.1536/ihj.18-299Isogai, T., Yasunaga, H., Matsui, H., et al. (2015) Effect of Intravenous Immunoglobulin for Fulminant Myocarditis on In-Hospital Mortality: Propensity Score Analyses. Journal of Cardiac Failure, 21, 391-397.
<br>https://doi.org/10.1016/j.cardfail.2015.01.004Takada, H., Kishimoto, C. and Hiraoka, Y. (1995) Therapy with Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model. Antiviral and Anti-Inflammatory Ef-fects. Circulation, 92, 1604-1611.
<br>https://doi.org/10.1161/01.CIR.92.6.1604Hafezi-Moghadam, A., Simoncini, T., Yang, Z., et al. (2002) Acute Cardiovascular Protective Effects of Corticosteroids Are Mediated by Non-Transcriptional Activation of Endothelial Ni-tric Oxide Synthase. Nature Medicine, 8, 473-479.
<br>https://doi.org/10.1038/nm0502-473Cooper, L.J., Berry, G.J. and Shabetai, R. (1997) Idiopathic Giant-Cell Myocarditis—Natural History and Treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. The New England Journal of Medicine, 336, 1860-1866.
<br>https://doi.org/10.1056/NEJM199706263362603Cooper, L.T. (2007) Giant Cell Myocarditis in Children. Progress in Pediatric Cardiology, 24, 47-49.
<br>https://doi.org/10.1016/j.ppedcard.2007.08.002Marcolongo, R., Rizzo, S., Cerutti, A., et al. (2021) The Mul-tiple Faces of Autoimmune/Immune-Mediated Myocarditis in Children: A Biopsy-Proven Case Series Treated with Im-munosuppressive Therapy. ESC Heart Failure, 8, 1604- 1609. <br>https://doi.org/10.1002/ehf2.13163Steinhaus, D., Gelfand, E., VanderLaan, P.A., et al. (2014) Recovery of Giant-Cell Myocarditis Using Combined Cytolytic Immu-nosuppression and Mechanical Circulatory Support. The Journal of Heart and Lung Transplantation, 33, 769-771. <br>https://doi.org/10.1016/j.healun.2014.02.018Chaudhry, M.A., Correa, A., Lee, C., et al. (2015) Modern Day Management of Giant Cell Myocarditis. International Journal of Cardiology, 178, 82-84. <br>https://doi.org/10.1016/j.ijcard.2014.10.131Grabmaier, U., Brenner, C., Methe, H., et al. (2013) An Alterna-tive Immunosuppressive Regimen to Prolong Transplant Free Survival in a Patient with Giant Cell Myocarditis. Interna-tional Journal of Cardiology, 168, e27-e28.
<br>https://doi.org/10.1016/j.ijcard.2013.05.078Hang, W., Chen, C., Seubert, J.M., et al. (2020) Fulminant Myo-carditis: A Comprehensive Review from Etiology to Treatments and Outcomes. Signal Transduction and Targeted Therapy, 5, 287.
<br>https://doi.org/10.1038/s41392-020-00360-yKraft, L., Erdenesukh, T., Sauter, M., et al. (2019) Blocking the IL-1beta Signalling Pathway Prevents Chronic Viral Myocarditis and Cardiac Remodeling. Basic Research in Cardiology, 114, 11.
<br>https://doi.org/10.1007/s00395-019-0719-0